Montelukast, a cysteinyl leukotriene
receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.
Godson, "Lipoxin, leukotriene
, and PDGF receptors cross-talk to regulate mesangial cell proliferation," The FASEB Journal, vol.
Comparison of therapeutic values between leukotriene
receptor antagonist (montelukast) and inhaled glucocorticoid (beclomethasone propionate) in bronchial asthma of adults.
Montelukast, a once daily leukotriene
receptor antagonist in the treatment of chronic asthma: a multicenter, randomised, doubleblind trial.
"At the onset of dementia, leukotrienes
attempt to protect nerve cells, but over the long term, they cause damage," Dr.
Capra, "Molecular and functional aspects of human cysteinyl leukotriene
receptors," Pharmacological Research, vol.
Authors stated previous research that "Prostaglandin E2 is involved in the classic signs of inflammation and possesses both pro-inflammatory and anti-inflammatory actions; thromboxane A2, formed by platelets, macrophages and polymorphonuclear leukocytes, can induce vasoconstriction and promotes aggregation of platelets as well as adhesiveness of polymorphonuclear neutrophils; leukotriene
B4 (LTB4) can not only increase vascular permeability and enhance local blood flow by stimulating neutrophil secretion, but also stimulate other inflammatory substances."
antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group.
 Patients were excluded if they had significant co-morbidities, were receiving oral corticosteroids, LABAs, leukotriene
antagonists or theophylline or had undergone an asthma exacerbation or lower respiratory tract infection within the four weeks prior to study entry.
There has been interest in whether leukotriene
modifiers may have a role in the management of COPD, although data have been relatively limited .
In the MK571 leukotriene
receptor antagonist group (n = 8), rats received MK571 (Sigma 7571) (0.1 mg/kg) by intraperitoneal administration 12 hr before nTi[O.sub.2] exposure.
On the other hand, women were significantly more adherent than men were for leukotriene
modifiers (0.499 vs.